ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Emergence, a Berkeley, Calif.-based life sciences technology development firm, and ExThera, a technology transfer partner of the Karolinska Institute in Stockholm, have formed a joint venture, ExThera Medical, to develop and market polymers for medical devices based on biologically active carbohydrates that remove pathogenic microorganisms, proteins, and cells from blood. The first clinical application for the technology will be in the treatment of sepsis in intensive care units. Emergence is a spin-off of Polymer Technology Group, which will provide R&D and manufacturing to ExThera Medical.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter